HK1054200A1 - 芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑 - Google Patents

芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑

Info

Publication number
HK1054200A1
HK1054200A1 HK03106504.3A HK03106504A HK1054200A1 HK 1054200 A1 HK1054200 A1 HK 1054200A1 HK 03106504 A HK03106504 A HK 03106504A HK 1054200 A1 HK1054200 A1 HK 1054200A1
Authority
HK
Hong Kong
Prior art keywords
antitumors
agents
monoclonal anti
aromatase inhibitors
her2 antibodies
Prior art date
Application number
HK03106504.3A
Other languages
English (en)
Inventor
G‧馬斯米尼
G‧皮斯特裡
D‧普蘭達爾
Original Assignee
法瑪西雅意大利公司
法瑪西雅厄普約翰美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法瑪西雅意大利公司, 法瑪西雅厄普約翰美國公司 filed Critical 法瑪西雅意大利公司
Publication of HK1054200A1 publication Critical patent/HK1054200A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03106504.3A 2000-05-15 2003-09-11 芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑 HK1054200A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (en) 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents

Publications (1)

Publication Number Publication Date
HK1054200A1 true HK1054200A1 (zh) 2003-11-21

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03106504.3A HK1054200A1 (zh) 2000-05-15 2003-09-11 芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑

Country Status (20)

Country Link
EP (1) EP1282440A1 (zh)
JP (1) JP2003533490A (zh)
KR (1) KR20030014223A (zh)
CN (1) CN1429118A (zh)
AU (1) AU784617B2 (zh)
BR (1) BR0110732A (zh)
CA (1) CA2409652A1 (zh)
CZ (1) CZ20023748A3 (zh)
EA (1) EA005931B1 (zh)
EE (1) EE200200622A (zh)
HK (1) HK1054200A1 (zh)
HU (1) HUP0301877A2 (zh)
IL (1) IL152389A0 (zh)
MX (1) MXPA02011194A (zh)
NO (1) NO20025302L (zh)
NZ (1) NZ523004A (zh)
PL (1) PL360153A1 (zh)
SK (1) SK16022002A3 (zh)
WO (1) WO2001087334A1 (zh)
ZA (1) ZA200209815B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
CN101711868A (zh) 2000-05-19 2010-05-26 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
EP1377298B1 (en) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
WO2003080835A1 (en) 2002-03-26 2003-10-02 Zensun (Shanghai) Sci-Tech. Ltd. Erbb3 based methods and compositions for treating neoplasms
PL374431A1 (en) * 2002-07-01 2005-10-17 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
EP2322217A3 (en) * 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
CN103432580A (zh) 2007-03-02 2013-12-11 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MX2011009729A (es) 2009-03-20 2011-10-14 Genentech Inc Anticuerpos anti-her.
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
JP2014526891A (ja) 2011-08-17 2014-10-09 ジェネンテック， インコーポレイテッド ニューレグリン抗体とその使用
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
CA2965372C (en) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CA3002562A1 (en) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
EP3976048A4 (en) 2019-06-03 2023-07-12 Havah Therapeutics Pty Ltd PHARMACEUTICAL FORMULATIONS AND SYSTEMS FOR THE ADMINISTRATION OF AN ANDROGEN AGENT AND AN AROMATASE INHIBITOR, AND METHODS OF USE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
NO20025302D0 (no) 2002-11-05
EA005931B1 (ru) 2005-08-25
EA200201213A1 (ru) 2003-04-24
WO2001087334A1 (en) 2001-11-22
SK16022002A3 (sk) 2003-04-01
CN1429118A (zh) 2003-07-09
HUP0301877A2 (hu) 2003-09-29
EP1282440A1 (en) 2003-02-12
AU5630901A (en) 2001-11-26
CZ20023748A3 (cs) 2003-04-16
NO20025302L (no) 2002-11-05
AU784617B2 (en) 2006-05-18
EE200200622A (et) 2004-06-15
ZA200209815B (en) 2003-12-03
JP2003533490A (ja) 2003-11-11
MXPA02011194A (es) 2003-03-10
NZ523004A (en) 2004-09-24
KR20030014223A (ko) 2003-02-15
CA2409652A1 (en) 2001-11-22
PL360153A1 (en) 2004-09-06
IL152389A0 (en) 2003-05-29
BR0110732A (pt) 2003-02-04

Similar Documents

Publication Publication Date Title
HK1054200A1 (zh) 芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑
HUP0300841A3 (en) Agonist anti-trk-c monoclonal antibodies
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
GB0029360D0 (en) Humanised antibodies and uses thereof
IL156030A0 (en) Humanized antibodies
AU1174702A (en) Humanized anti-lt-beta-r antibodies
HK1158219A1 (zh) 細胞亞群特異單克隆和多克隆抗體的組合物和方法
PL354112A1 (en) Application of anti-ctla-4 antibodies
EP1391464A4 (en) ANTI-CD40 MONOCLONAL ANTIBODY
HK1153763A1 (en) Anti-her2 antibody variants
IL166244A0 (en) Super humanized antibodies
EP1448601A4 (en) METHOD AND COMPOSITIONS OF MONOCLONAL ANTIBODIES SPECIFIC TO BETA-AMYLOIDE PROTEINS
EP1572077A4 (en) USES OF MONOCLONAL 8H9 ANTIBODIES
EP1399187A4 (en) APPLICATIONS OF MONOCLONAL ANTIBODY 8H9
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2001277022A1 (en) Bispecific monoclonal antibodies to il-12 and il-18 receptors
AU2003220079A8 (en) Uses of monoclonal antibody 8h9
EP1178829A4 (en) HUMAN MONOCLONAL ANTIBODY
FI20011055A (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
EP1446416A4 (en) TUMOR-SPECIFIC MONOCLONAL ANTIBODIES
GB0003359D0 (en) Monoclonal antibodies
GB0008160D0 (en) Monoclonal antibodies
GB0029846D0 (en) Monoclonal antibody
GB0030139D0 (en) Monoclonal antibody
GB0020794D0 (en) Humanised antibodies